AstraZeneca PLC
Global biopharma developing medicines for oncology, cardiovascular, respiratory & rare diseases.
AZN | IL
Overview
Corporate Details
- ISIN(s):
- GB0009895292 (+925 more)
- LEI:
- PY6ZZQWO2IZFZC3IOL08
- Country:
- United Kingdom
- Address:
- 1 FRANCIS CRICK AVENUE, CB2 0AA CAMBRIDGE
- Website:
- https://www.astrazeneca.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. The company's primary therapeutic areas include Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Diseases. AstraZeneca develops, manufactures, and sells pharmaceutical and biotechnology products aimed at addressing complex health challenges for millions of patients worldwide. The firm maintains a significant research and development pipeline to create innovative treatments and transform healthcare through scientific advancement.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-29 08:30 |
Earnings Release
Enhertu improved IDFS in early BC in DB-05
|
English | 35.9 KB | ||
| 2025-09-29 08:04 |
Registration Form
Proposed new Articles of Association of AstraZeneca PLC
|
English | 740.9 KB | ||
| 2025-09-29 08:04 |
Registration Form
Existing Articles of Association of AstraZeneca PLC marked up to show proposed …
|
English | 804.3 KB | ||
| 2025-09-29 08:00 |
Pre-Annual General Meeting Information
AZN harmonises listing structure
|
English | 16.3 KB | ||
| 2025-09-29 07:58 |
Proxy Solicitation & Information Statement
Form of Proxy
|
English | 144.8 KB | ||
| 2025-09-29 07:53 |
Pre-Annual General Meeting Information
Circular and Notice of General Meeting
|
English | 397.9 KB | ||
| 2025-09-25 17:30 |
Director's Dealing
Director/PDMR Shareholding
|
English | 21.4 KB | ||
| 2025-09-22 08:05 |
Regulatory News Service
Koselugo recommended for EU approval
|
English | 21.4 KB | ||
| 2025-09-22 08:00 |
Regulatory News Service
Tezspire Recommended for Approval in EU for CRSwNP
|
English | 33.6 KB | ||
| 2025-09-17 08:05 |
Regulatory News Service
Saphnelo met primary endpoint in TULIP-SC
|
English | 27.3 KB | ||
| 2025-09-17 08:00 |
Regulatory News Service
Update on RESOLUTE Phase III trial
|
English | 22.5 KB | ||
| 2025-08-28 16:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 8.2 KB | ||
| 2025-08-26 16:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 25.9 KB | ||
| 2025-08-26 10:57 |
Major Shareholding Notification
|
Swedish | 10.9 KB | ||
| 2025-08-21 16:00 |
Major Shareholding Notification
Holding(s) in Company
|
English | 25.7 KB |
Automate Your Workflow. Get a real-time feed of all AstraZeneca PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for AstraZeneca PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-03-06 | Pascal Soriot | Other | Other | 8,853 | N/A |
| 2023-03-04 | Pascal Soriot | Other | Other | 100,256 | 10,848,701.76 EUR |
| 2023-03-04 | Aradhana Sarin | Other | Other | 45,449 | 4,918,036.29 EUR |
| 2023-02-09 | Pascal Soriot | Other | Other | 15,187 | N/A |
| 2022-12-23 | Pascal Soriot | Other | Other | 163,838 | N/A |
| 2022-03-24 | Pascal Soriot | Other | Other | 129,784 | N/A |
| 2022-03-08 | Pascal Soriot | Other | Other | 9,930 | N/A |
| 2022-02-10 | Pascal Soriot | Other | Other | 24,124 | N/A |
| 2021-09-30 | Pascal Soriot | Other | Other | 231,922 | N/A |
| 2021-08-13 | Aradhana Sarin | Other | Other | 31,690 | 2,601,432.10 EUR |
